Skip to main content
Premium Trial:

Request an Annual Quote

Roe Joins Celera's Board, Genomic Health Appoints Graham to Board, Fronczkowski to Leave Strategic Dx, and More

NEW YORK (GenomeWeb News) – Celera has named Wayne Roe as a director of the company. Roe is a general partner for medical technology fund DFJ In-Cube Ventures. He also currently sits on the executive committee of the Maryland Angels Fund as well as the board of directors of ISTA Pharmaceuticals. Roe previously was chairman of Covance Health Economics and Outcomes Services.

Genomic Health said that it has appointed Ginger Graham to its board of directors. Graham is a former president and CEO of Amylin Pharmaceuticals. Prior to that role, she was group chairman, office of the president, at Guidant. She also has held a number of management positions at Eli Lilly.

Helicos BioSciences disclosed in a filing with the US Securities and Exchange Commission this week that Ronald Lowy, whom the firm appointed as CEO last week, will perform his duties on a part-time basis and receive an annual salary of $240,000. The firm also announced that Chairman Stanley Lapidus will provide business consulting services to the firm for $7,000 per month.

Signature Genomic Laboratories said that Lewis Rumpler has been named vice president of business development. Prior to joining Signature, he was COO of the Institute for Systems Medicine Planning Authority. Rumpler also previously served as CEO of Pacific Northwest Biotechnology.

Stanley Fronczkowski is stepping down from his role of CFO at Strategic Diagnostics effective April 3, 2009. The firm said that he is leaving to pursue other interests, and that it will initiate a search for a new CFO.

Eurogentec has named Diane Wolfe to be general manager of its North American operations, based in San Diego. Wolfe formerly was vice president of manufacturing for Celera and was senior director of oligonucleotide technology at Roche Molecular Systems.

Anne Wojcicki, co-founder of 23andMe, has been named to the board of directors of the Foundation for the National Institutes of Health. She was one of five new directors announced this week. The others are Pfizer Chief Medical Officer Joseph Feczko; Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft; Kurt Schmoke, dean of Howard University School of Law; and Samuel Thier, professor emeritus, medicine and health care policy at Harvard Medical School and Massachusetts General Hospital.

Affymetrix said that Vernon Loucks will retire from its board of directors effective Jan. 1, 2009. His spot on the board will be filled by Affymetrix President and CEO Kevin King.
In addition, Affy disclosed in a filing with the US Securities and Exchange Commission that King will receive an increase in his annual base salary to $675,000 from $500,000. He also will be eligible for a target cash bonus of 75 percent of his annual salary.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.